Search
Fluciclovine
go.drugbank.com/drugs/DB15237InvestigationalFluciclovine is under investigation in clinical trial NCT03036943 (Fluciclovine (18F) Imaging of Breast Cancer).
Categories: P-glycoprotein inhibitorsTovorafenib
go.drugbank.com/drugs/DB15266ApprovedInvestigationalTovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, wi...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersDexlansoprazole
go.drugbank.com/drugs/DB05351ApprovedDexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of DB00448, which is ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBrivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesTirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigationalTirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsRomidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesZiconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigationalZiconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail Conus magus comprising 25 amino acids with three disulphide bonds. Other such peptides, collectively termed conotoxins, exist, and some have shown eff...
Tafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigationalTafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine th...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesChenodeoxycholic acid
go.drugbank.com/drugs/DB06777ApprovedInvestigationalChenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBefunolol
go.drugbank.com/drugs/DB09013ExperimentalBefunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates